Royalty Pharma | DEFA14A: Others
Royalty Pharma | SCHEDULE 13D/A: Others
Royalty Pharma | 4: Statement of changes in beneficial ownership of securities-Officer Hite Christopher
Royalty Pharma | PREM14A: Preliminary proxy statements relating to merger or acquisition
Royalty Pharma | 10-K: FY2024 Annual Report
Royalty Pharma | SCHEDULE 13G/A: Others
Royalty Pharma | 8-K: Current report
Royalty Pharma | SCHEDULE 13G: Others
Royalty Pharma | DEFA14A: Others
Royalty Pharma | DEFA14A: Others
Royalty Pharma | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
Royalty Pharma | DEFA14A: Others
Royalty Pharma | 8-K: Current report
Royalty Pharma | DEFA14A: Others
Royalty Pharma | 8-K: Current report
Royalty Pharma | 8-K: Current report
Royalty Pharma | 4: Statement of changes in beneficial ownership of securities-Director Fernandez Henry A
Royalty Pharma | 4: Statement of changes in beneficial ownership of securities-Director Bassler Bonnie L
Royalty Pharma | 8-K: Current report
Royalty Pharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Morgan Stanley(8.2%),Morgan Stanley Investment Management Inc.(7.6%)